Berbamine Cancer Research Results

BBM, Berbamine: Click to Expand ⟱
Features:

Berbamine — berbamine is a natural bisbenzylisoquinoline alkaloid with pleiotropic anticancer signaling activity. It is best classified as a plant-derived small-molecule natural product and investigational anticancer lead rather than an approved oncology drug. Standard abbreviation: BBM. It is chiefly isolated from Berberis species, especially Berberis amurensis, and has also been reported in other alkaloid-containing medicinal plants. The strongest mechanistic signal in cancer appears to be inhibition of CaMKIIγ-centered survival signaling, with downstream effects on c-Myc, STAT3, β-catenin, PI3K/Akt-related survival programs, apoptosis, and in some models ROS-linked stress responses. Clinical oncology translation remains limited; most evidence is preclinical, and formulation constraints have been noted because native berbamine has limited tumor-site exposure and short plasma persistence in vivo.

Primary mechanisms (ranked):

  1. Direct or functionally dominant inhibition of CaMKIIγ signaling, especially in leukemia stem/progenitor and MYC-driven settings
  2. Downregulation of c-Myc stability and associated survival programs
  3. Suppression of JAK/STAT3 and related stemness / inflammatory oncogenic signaling
  4. Inhibition of PI3K/Akt and MDM2-p53 survival signaling with promotion of apoptosis
  5. Induction of mitochondrial / caspase-linked apoptosis and cell-cycle arrest
  6. Context-dependent ROS elevation contributing to cytotoxic stress and drug sensitization
  7. Anti-migration / anti-invasion effects including EMT-related suppression in some solid-tumor models
  8. Clinical translation constraint from limited native exposure, short half-life, and dependence on formulation or derivative optimization

Bioavailability / PK relevance: Native berbamine appears PK-limited for systemic oncology use. Multiple papers describe short plasma half-life or poor tumor-site exposure as a practical limitation, which is one reason nanoparticle and derivative strategies have been pursued. I did not find a robust modern human PK package for parent berbamine suitable for quantitative clinical extrapolation; stronger PK data were easier to find for derivatives than for the native compound.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar in-vitro concentrations, often around 5–20 μM and sometimes higher. That makes direct translation to achievable free systemic exposure uncertain for native berbamine. Mechanistic direction is plausible, but potency-to-exposure matching remains a major translational bottleneck unless formulation or structural optimization is used.

Clinical evidence status: Preclinical for cancer. Evidence includes cell culture and xenograft studies across leukemia and several solid tumors, plus medicinal-chemistry optimization work on derivatives. I did not find established randomized oncology trials or standard clinical deployment for cancer treatment.

Berbamine is a bisbenzylisoquinoline alkaloid, meaning it is composed of two benzylisoquinoline moieties. Its unique structure distinguishes it from many other natural alkaloids Berbamine is most often isolated from the plant Berberis, commonly known as barberry. Various species within this genus have been used in traditional Chinese medicine and other herbal traditions. plants in genera like Stephania have also been reported to contain bisbenzylisoquinoline alkaloids like berbamine. These plants are used in various parts of Asia both for their stimulant effects and other medicinal purposes.

Oxidative Stress:
Berbamine can increase the production of reactive oxygen species within cancer cells. Elevated ROS levels may push cancer cells beyond their threshold of tolerance, leading to oxidative stress–induced cell death. This property also ties in with its ability to modulate apoptosis and autophagy.

Berbamine is a promising natural compound with multifaceted anticancer properties. Its ability to induce apoptosis, cause cell cycle arrest, modulate key signal transduction pathways (such as JAK/STAT, NF-κB, and PI3K/Akt/mTOR), and affect autophagy, makes it a candidate for further investigation in various cancer models.

A calcium channel blocker.

Mechanistic relevance in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CaMKIIγ ↓ ↔ / ↓ R Collapse of stemness-survival signaling Best-supported central axis. In CML and MYC-driven hematologic models, berbamine directly targets the ATP-binding pocket of CaMKIIγ, with downstream suppression of leukemia stem/progenitor signaling.
2 c-Myc stability ↓ ↔ R-G Reduced oncogenic transcriptional drive Mechanistically linked to CaMKIIγ inhibition; relevant in lymphoma, leukemia, and gastric cancer models. This is one of the strongest industry-relevant translation axes.
3 JAK / STAT3 ↓ ↔ / ↓ R-G Reduced proliferation, survival, stemness, inflammation Frequently reported across cancer models and also coherent with the CaMKIIγ network in leukemia stem cells. Strong but somewhat model-dependent outside hematologic disease.
4 PI3K / Akt survival signaling ↓ ↔ R-G Growth inhibition and apoptosis sensitization Supported in lung and other solid-tumor systems; likely important but not as central as CaMKIIγ / c-Myc / STAT3.
5 MDM2 / p53 apoptotic control MDM2↓ p53↑ ↔ G Apoptosis induction Observed in CRC and lung cancer models. Relevance depends on p53 status; strongest where apoptotic machinery remains inducible.
6 Mitochondrial apoptosis ↑ caspase activation ↔ / dose-dependent injury G Execution-phase cell death A recurrent downstream phenotype rather than a unique upstream target. Fits with anti-proliferative and pro-apoptotic readouts in xenograft-backed studies.
7 Reactive oxygen stress secondary ↑ (context-dependent) ↔ / injury at higher concentration R-G Stress amplification and sensitization ROS increase is reported in some models and in derivative work, but it is better treated as secondary/contextual rather than the core unifying mechanism.
8 Migration / invasion / EMT programs ↓ ↔ G Anti-metastatic effect Supported in selected solid-tumor and nanoparticle-formulation studies. Useful translationally, but less central mechanistically than survival-axis suppression.
9 Clinical Translation Constraint Limited exposure matching n/a G Constrains systemic deployment Native berbamine has limited exposure durability and formulation dependence; several groups moved toward nanoparticles or derivatives to improve delivery, potency, and bioavailability.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Scientific Papers found: Click to Expand⟱
5546- BBM,    Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II
- vitro+vivo, Liver, NA
TumCP↓, CaMKII ↓,
5556- BBM,    Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells
- in-vitro, Melanoma, NA
TumCP↓, eff↑, TumCCA↑, IKKα↓, p65↓, Bcl-xL↓, BID↓, survivin↓,
5555- BBM,    Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells
- vitro+vivo, RCC, NA
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, toxicity↓, FTO↑,
5554- BBM,  SRF,    Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
ChemoSen↑, STAT3↓,
5553- BBM,    A review on berbamine–a potential anticancer drug
- Review, Var, NA
P-gp↓, MDR1↓, survivin↓, NF-kB↓, TumCP↓, TumCCA↑, Apoptosis↑, SMAD3↑, P21↑, cycD1/CCND1↓, cMyc↑, Bcl-2↓, Bcl-xL↓, BAX↑, CaMKII ↓, ChemoSen↑, MMP2↓, MMP9↓, TIMP1↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, cl‑PARP↑, IL6↓, ROS↑,
5552- BBM,    Effects of berbamine against myocardial ischemia/reperfusion injury: Activation of the 5' adenosine monophosphate‐activated protein kinase/nuclear factor erythroid 2‐related factor pathway and changes in the mitochondrial state
- in-vivo, Stroke, NA
*eff↑, *ROS↓, *mtDam↓, *AMPK↑, *NRF2↑, *NADPH↑, *HO-1↑, *cardioP↑,
5551- BBM,    Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis
- vitro+vivo, Bladder, NA
tumCV↓, TumCP↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, EMT↓, TumMeta↓, p65↓, p‑p65↓, IKKα↓, NF-kB↑, ROS↑, NRF2↓, HO-1↓, SOD2↓, GPx1↓, Bax:Bcl2↑, TumVol↓,
5550- BBM,  docx,  Chit,    Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities
- in-vivo, Var, NA
eff↑, BioAv↑, Apoptosis↑, survivin↓,
5549- BBM,    Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells
- in-vitro, GBM, NA
eff?, tumCV↓, TumCG↓, ROS↑, P53↑, CSCs↓, CD133↓, ALDH1A1↓, Nanog↓, SOX2↓, OCT4↓, CDK1↓, CaMKII ↓, STAT3↓, Akt↓, ERK↓,
5547- BBM,    Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway
- in-vitro, CRC, HT29
tumCV↓, selectivity↑, Casp3↑, Casp9↑, Bax:Bcl2↑, ATG5↑, Beclin-1↑, TumCP↓, MEK↓, ERK↓,
1242- BBM,    Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways
- in-vivo, Nor, NA
*Macrophages↓, *Neut↓, *p‑NF-kB↓, *p‑MAPK↓, *p‑JNK↓, *p‑ERK↓,
5544- BBM,    Berbamine promotes macrophage autophagy to clear Mycobacterium tuberculosis by regulating the ROS/Ca2+ axis
- in-vitro, AML, THP1
ROS↑, Ca+2↑,
5543- BBM,    Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo
- in-vivo, Lung, B16-F10 - vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-231
BioAv↓, Half-Life↓, eff↑, TumMeta↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, MMP2↓, MMP9↓, VEGF↓, Bcl-2↓, eff↑, EPR↑,
5542- BBM,    Pharmacological profiling of a berbamine derivative for lymphoma treatment
- vitro+vivo, lymphoma, NA
CaMKII ↓, TumCG↓, cMyc↓, ROS↑, UPR↑, ER Stress↑, PERK↑, BioAv↑, toxicity↓,
5541- BBM,    Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, TumCCA↑, Apoptosis↑, BRD4↓, selectivity↑, TumCG↓, cMyc↓,
5540- BBM,    Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCI↓, PI3K↓, Akt↓, MDM2↓, TumCP↓, TumMeta↓,
5539- BBM,    Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway
- vitro+vivo, CRC, SW480
tumCV↓, TumCCA↑, MMP↓, P53↑, Casp3↑, Casp9↑, BAX↑, PARP↑, Bcl-2↓, TumVol↑,
5538- BBM,    Stabilization of the c-Myc protein by CAMKIIγ promotes T cell lymphoma
- Review, lymphoma, NA
CaMKII ↓, cMyc↝,
5537- BBM,    CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine
- in-vitro, CLL, NA
CaMKII ↓, NF-kB↓, IKKα↓, p‑STAT3↓,
5536- BBM,    Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers
- Review, Var, NA
JAK↝, STAT3↓, p‑CaMKII ↓, TGF-β↑, Smad1↑, ChemoSen↑, RadioS↑, TumCI↓, TumCMig↓, ROS↑, NRF2↓, SOD2↓, GPx1↓, HO-1↓,

Showing Research Papers: 1 to 20 of 20

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 20

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

BRD4↓, 1,  

Redox & Oxidative Stress ⓘ

GPx1↓, 2,   HO-1↓, 2,   NRF2↓, 2,   ROS↑, 6,   SOD2↓, 2,  

Mitochondria & Bioenergetics ⓘ

MEK↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   cMyc↑, 1,   cMyc↝, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 4,   BAX↑, 2,   Bax:Bcl2↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 2,   BID↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   MDM2↓, 1,   p27↑, 1,   survivin↓, 3,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 6,   p‑CaMKII ↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 2,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CSCs↓, 1,   EMT↓, 1,   ERK↓, 2,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 1,   SOX2↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TumCG↓, 5,  

Migration ⓘ

Ca+2↑, 1,   FTO↑, 1,   MMP2↓, 2,   MMP9↓, 2,   Smad1↑, 1,   SMAD3↑, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 9,   TumMeta↓, 3,  

Angiogenesis & Vasculature ⓘ

EPR↑, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IKKα↓, 3,   IL6↓, 1,   JAK↝, 1,   NF-kB↓, 2,   NF-kB↑, 1,   p65↓, 2,   p‑p65↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 3,   eff?, 1,   eff↑, 4,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 2,   TumVol↓, 1,   TumVol↑, 1,  
Total Targets: 90

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Mitochondria & Bioenergetics ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   NADPH↑, 1,  

Cell Death ⓘ

p‑JNK↓, 1,   p‑MAPK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,  

Immune & Inflammatory Signaling ⓘ

Macrophages↓, 1,   Neut↓, 1,   p‑NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,  
Total Targets: 14

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:40  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page